Overture to continue
Wednesday, 11 June, 2008
Independent regulators have recommended the continuation of the Ovature ovarian cancer trial, being run by Novogen's (ASX: NRT) subsidiary Marshall Edwards.
The trial's Independent Data Monitoring Committee (IDMC) recommended the continuation of the phase III trial of the orally administered investigational drug phenoxodiol, a chemosensitising agent, in women with advanced, refractory ovarian cancer.
The trial is being run to determine its safety and effectiveness when used in combination with carboplatin.
The trial has been approved by the US FDA under a special protocol assessment program. It is recruiting patients in clinical sites across the US, UK, Europe and Australia.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
